These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma.
    Author: Yaegashi H, Izumi K, Kadomoto S, Naito R, Makino T, Iwamoto H, Nohara T, Shigehara K, Kadono Y, Mizokami A.
    Journal: Anticancer Res; 2019 Jan; 39(1):375-380. PubMed ID: 30591483.
    Abstract:
    BACKGROUND: The present study was conducted to investigate whether baseline serum carbohydrate antigen (CA) 19-9 predicts prognosis or treatment effect in patients with advanced urothelial carcinoma (UC). MATERIALS AND METHODS: We retrospectively analyzed data of patients diagnosed with locally advanced or metastatic or recurrent UC between April 2008 and November 2014. CA19-9 was determined using enzyme-linked immunosorbent assay (ELISA) and the relationship between CA19-9 and prognosis were analyzed. RESULTS: Of 40 patients, seven with CA19-9 ≤2 U/ml who were suspected of having Lewis A-negative blood type and two patients with advanced metastatic liver disease were excluded. UC-specific survival in metastatic disease significantly correlated with prognosis (p=0.018). Overall survival in patients with high serum CA19-9 demonstrated a significantly better prognosis than in those with low concentrations (log-rank test, p=0.032). CONCLUSION: High baseline serum CA19-9 may predict a good prognosis in patients with advanced UC.
    [Abstract] [Full Text] [Related] [New Search]